Clinical trials: Essential Hypertension.
Hypertension, Aromatherapy
The Effect of Aromatherapy on Sleep, Anxiety and Vital Signs in Those With Essential Hypertension (Hypertension)
In addition to pharmacological agents in the treatment of hypertension, it has been reported in studies that aromatherapy applications, one of the traditional and complementary alternative treatments that are easy to apply…
- Trial name
- hypertension (NCT06482424)
- Testing
- intervention group
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- TC Erciyes University
Essential Hypertension
BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination
The objective of this clinical study is to evaluate the efficacy and safety by comparing the BR1010 treatment group to the fimasartan/amlodipine treatment group at Week 8 in patients with essential hypertension who do not…
- Trial name
- FINAL (NCT03991442)
- Testing
- Fimasartan/Amlodipine
- Where
- South Korea
- Volunteers
- 257 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
A Study to Evaluate the Combination of Valsartan + Amlodipine in Hypertensive Patients
The purpose of this study is to evaluate the efficacy of valsartan plus amlodipine in hypertensive patients not responding to treatment with amlodipine or felodipine alone.
- Trial name
- NCT00392262
- Testing
- valsartan + amlodipine
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 224 people
- Sponsor
- Novartis
Essential Hypertension
Evaluation of Effect of Combination With Telmisartan and Hydrochlorothiazide in Hypertensives Uncontrolled on Amlodipine
The purpose of this study is to compare depressor effect and safety between combination therapy with telmisartan plus low-dose hydrochlorothiazide and amlodipine in hypertensive patients.
- Trial name
- ONEAST (NCT00509470)
- Testing
- telmisartan plus hydrochlorothiazide, Amlodipine
- Where
- Japan
- Volunteers
- 75 people
- Sponsor
- Tokyo University
Hypertension,Essential
Association Between Coronary Flow Reserve and BH4 Levels in High CV Risk
To determine if there is a relationship between coronary flow reserve (CFR) and platelet/plasma BH2 and BH4 levels in patients with high cardiovascular risk .
- Trial name
- NCT03841383
- Testing
- Echo stress dipyridamole
- Where
- 2 sites in Italy
- Volunteers
- 55 people
- Sponsor
- IRCCS San Raffaele
Essential Hypertension
Effects of Valsartan vs Amlodipine and Low BP on Kidney Outcomes in Essential Hypertension
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial tested the hypothesis that for the same blood-pressure control, valsartan would reduce cardiac morbidity and mortality more than amlodipine in hypertensive…
- Trial name
- VALUE (NCT06395194)
- Testing
- Cardiac outcomes on treatment with valsartan, Cardiac outcomes on treatment with amlodipine
- Volunteers
- 15,313 people
- Sponsor
- Oslo University Hospital
Primary Hypertension
Bioequivalence Study of Sacubitril Alisartan Amlodipine Tablets
This study aims to evaluate the bioequivalence and safety of single oral administration of Sacubitril/Valsartan/Amlodipine Tablets (240mg/5mg) versus Sacubitril/Valsartan Calcium Tablets (240mg) combined with Amlodipine Besylate…
- Trial name
- NCT07486453
- Testing
- Sequence A T-R-T-R, Sequence B R-T-R-T
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Hypertension,Essential
Safety and Efficacy of SPH3127 on Treating Mild-moderate Essential Hypertension Patients
SPH3127 tablet is a of renin inhibitor. It is expected to be a new drug for essential hypertension. This is a phase IIa trial which designed to evaluate its efficacy and safety on treating mild-moderate essential hypertension…
- Trial name
- NCT03756103
- Testing
- SPH3127 tablet Dose 1, SPH3127 tablet Dose 2, SPH3127 tablet Dose 3
- Where
- 10 sites in China
- Volunteers
- 120 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Hypertension, Hypertension, Essential
Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension
The purpose of this study is to better understand the cardiovascular effects of the vasodilatory peptide Angiotensin (1-7) in human hypertension.
- Trial name
- NCT02245230
- Testing
- Angiotensin (1-7), Trimethaphan, Phenylephrine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Vanderbilt University
Hypertension
To Evaluate the Efficacy and Safety of KN060 in Essential Hypertension
The primary objective of this study is to compare the change from baseline in systolic blood pressure between KN060 and placebo in patients with essential hypertension over 12 weeks; the secondary objectives are to assess the…
- Trial name
- NCT07191899
- Testing
- KN060, 0.9% Sodium Chloride Injection
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Suzhou Alphamab Co., Ltd.
Essential Hypertension
Effectiveness and Patient Self-assessed Compliance of Blood Pressure Treatment With Tarka® Fixed Combination in Patients With Essential Hypertension
The fixed combination of verapamil SR/trandolapril (Tarka®) is an effective, well-tolerated therapy for the treatment of essential hypertension in those who require more than one agent to achieve optimal blood pressure (BP)…
- Trial name
- NCT01127139
- Where
- 134 sites in Czechia
- Volunteers
- 3,828 people
- Sponsor
- Abbott
Essential Hypertension
Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
This study assessed the efficacy and safety of the valsartan/amlodipine 160/5 mg single-pill combination in patients with uncomplicated essential hypertension not adequately controlled (MSDBP ≥90 mmHg and <110 mmHg) on valsartan…
- Trial name
- NCT01001572
- Testing
- Valsartan/amlodipine 160/5 mg, Valsartan 160 mg
- Volunteers
- 932 people
- Sponsor
- Novartis
Essential Hypertension
A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of Candesartan/Amlodipine combined or alone and select better dose of CKD-330 in essential hypertension patients.
- Trial name
- NCT02206165
- Testing
- Candesartan 8mg, Candesartan 16mg, Amlodipine 5mg
- Where
- South Korea
- Volunteers
- 456 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Essential Hypertension
Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients
This prospective multicenter, double blind study will evaluate the efficacy and safety of aliskiren versus ramipril in patients with moderate systolic essential hypertension.
- Trial name
- ALIAS (NCT01042392)
- Testing
- Aliskiren, Ramipril
- Where
- 98 sites in France
- Volunteers
- 506 people
- Sponsor
- Novartis
Essential Hypertension, Primary Hypercholesterolemia
A Study to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary Hypercholesterolemia
The objective of this clinical study is to evaluate the efficacy and safety by comparing BR1017A+BR1017B treatment group to BR1017A treatment group and BR1017B treatment group respectively at Week 8 in essential hypertension…
- Trial name
- NCT05930028
- Testing
- Fimasartan, Ezetimibe/Atorvastatin
- Where
- South Korea
- Volunteers
- 148 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Essential Hypertension
Use of the Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension
The study will evaluate the blood pressure lowering effects of two different dosages of the combination of olmesartan and hydrochlorothiazide in patients with moderate or severe high blood pressure.
- Trial name
- NCT00430508
- Testing
- olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets, olmesartan medoxomil/hydrochlorothiazide tablets
- Where
- 55 sites in Bulgaria, Czechia and 5 more
- Volunteers
- 972 people
- Sponsor
- Daiichi Sankyo
Hypertension
A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal.
To compare the aliskiren regimen versus the ramipril regimen on reduction in Blood Pressure.
- Trial name
- NCT00219063
- Testing
- aliskiren
- Where
- United States
- Volunteers
- 844 people
- Sponsor
- Novartis
Hypertension,Essential
Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized Controlled Trial
The purpose of this study is: 1. To evaluate the efficacy of Songling Xuemaikang Capsules(SLXMKC) with grade 1 hypertension. 2. To reveal the potiential effects of SLXMKC on vascular function and structure of patients with grade…
- Trial name
- ESCIHP (NCT06093932)
- Testing
- Songling Xuemaikang Capsules, Lifestyle intervention
- Where
- 5 sites in China
- Volunteers
- 100 people
- Sponsor
- Xiyuan Hospital of China Academy of Chinese Medical Sciences
Essential Hypertension
Study MIPAE - Melatonin and Essential Arterial Hypertension
Study MIPAE - Melatonin and essential arterial hypertension. Study with dietary supplement, prospective and monocentric (randomized control trial).
- Trial name
- MIPAE (NCT05257291)
- Testing
- Melatonin
- Where
- Italy
- Volunteers
- 23 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Hypertension (HTN), NYHA Class III Heart Failure
Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension
Objective: This study aims to evaluate the safety and efficacy of the fixed-dose triple combination therapy (SPC1001 Low) of candesartan, amlodipine, and indapamide in adult patients with essential hypertension compared to…
- Conditions
- Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure, Diabete Mellitus
- Trial name
- NCT07064525
- Testing
- SPC1001 Low, SPC5002, SPC5003
- Where
- South Korea
- Volunteers
- 252 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.